Alexander Lynge Reese-Petersen (Alexander L Reese-Petersen)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 8

Top Topics

Cardiac Resynchronization Therapy

Peritoneal Dialysis

Patient Reported Outcomes

Ejection Fraction

Top Venues

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander Lynge Reese-Petersen, Helene W Breisnes, Daniel Gabor, Sarah R Rønnow, Bruna Manoel, Mayuur Bajaj, Claus S von Arenstorff, Elijah Aighobahi, Rune Vestermark, Morten A Karsdal
Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 29 (4) (2024)
Alexander Lynge Reese-Petersen, Helene W Breisnes, Daniel Gabor, Sarah R Rønnow, Bruna Manoel, Mayuur Bajaj, Claus S von Arenstorff, Elijah Aighobahi, Rune Vestermark, Morten A Karsdal
Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2024)
Alexander Lynge Reese-Petersen, Helene W Breisnes, Daniel Gabor, Sarah R Rønnow, Bruna Manoel, Mayuur Bajaj, Claus S von Arenstorff, Elijah Aighobahi, Rune Vestermark, Morten A Karsdal
Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 29 (4) (2024)
Alexander Lynge Reese-Petersen, Signe Holm Nielsen, Jannie Marie Bülow Sand, Jörn M Schattenberg, Elisabetta Bugianesi, Morten A Karsdal
The sclerotic component of metabolic syndrome: Fibroblast activities may be the central common denominator driving organ function loss and death. Diabetes, obesity & metabolism 26 (7) (2024)
Alexander Lynge Reese-Petersen, Helene W Breisnes, Daniel Gabor, Sarah R Rønnow, Bruna Manoel, Mayuur Bajaj, Claus S von Arenstorff, Elijah Aighobahi, Rune Vestermark, Morten A Karsdal
Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2024)
Alexander Lynge Reese-Petersen, Signe Holm Nielsen, Jannie Marie Bülow Sand, Jörn M Schattenberg, Elisabetta Bugianesi, Morten A Karsdal
The sclerotic component of metabolic syndrome: Fibroblast activities may be the central common denominator driving organ function loss and death. Diabetes, obesity & metabolism 26 (7) (2024)
Alexander Lynge Reese-Petersen, Helene W Breisnes, Daniel Gabor, Sarah R Rønnow, Bruna Manoel, Mayuur Bajaj, Claus S von Arenstorff, Elijah Aighobahi, Rune Vestermark, Morten A Karsdal
Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 29 (4) (2024)
Alexander Lynge Reese-Petersen, Signe Holm Nielsen, Jannie Marie Bülow Sand, Jörn M Schattenberg, Elisabetta Bugianesi, Morten A Karsdal
The sclerotic component of metabolic syndrome: Fibroblast activities may be the central common denominator driving organ function loss and death. Diabetes, obesity & metabolism (2024)